MedTrace Logo

Interaction Study of Rapamycin and Sunitinib in Patients With Advanced Cancers

NCT00583063 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2013-06-12

No results posted yet for this study

Summary

Determine the pharmacokinetic interactions between rapamycin and sunitinib in patients with advanced solid tumors.

Conditions

Interventions

DRUG

sunitinib

25 mg daily (oral dosing)

DRUG

rapamycin

4 mg daily (oral dosing)

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • University of Chicago

    lead OTHER

Principal Investigators

  • Ezra Cohen, MD · University of Chicago

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2008-04-30
Completion
2008-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00583063 on ClinicalTrials.gov